May. 8 at 1:42 PM
$NXGL Recent acquisition increases the annual revenues to
$35 million, increases gradually, assuming full exercise, to ~29 million shares, turns the company to profitability, with zero debt.
Metrics around
$0.60 look favorable with low EV/Sales, etc.
Price of the Sequence LifeScience™ investment convertible at
$0.60, further warrants at
$0.80.
Therefore, buying at
$0.60 you bet with Sequence, a firm that has deep knowledge of the sector and has made some good investments in the recent past.
For long term hold, more high margin products have already planned to be out to the market in 2027 and beyond.
For short term trading, the chart looks decent now, with the sp dropped due to a weak Q4, but with CEO stating that Q1 will be back to normal (check last CC).
